On the 2nd, as the domestic stock market experienced a simultaneous decline in both the KOSPI and KOSDAQ due to foreign selling and weakness in semiconductor stocks, Alteogen, a large-cap KOSDAQ stock, continued its upward trend, drawing strong market interest.

That morning, Alteogen traded at 360,500 won, up 2,500 won (0.70%) from the previous trading day. After rising to as high as 364,500 won early in the session and demonstrating strength, trading continued in positive territory.

Domestic market investor sentiment contracted as the U.S. semiconductor stock correction and foreign selling coincided. With the bearish market continuing in both the KOSPI and KOSDAQ, and a significant number of large-cap stocks under downward pressure, Alteogen showed a relatively steady trend driven by expectations for its individual growth.

Market analysis suggests that expectations for Alteogen's platform technology competitiveness and the potential for global business expansion continue to persist. The company is expanding cooperation with global pharmaceutical companies based on 'ALT-B4,' its proprietary subcutaneous (SC) injection formulation conversion platform, and continues research and development in the fields of antibody-drug conjugates (ADC) and biopharmaceuticals.

Recently, with the disclosure that the first licensing partner for ALT-B4 is Sanofi, expectations for global technology commercialization have further increased. Evaluations suggest that the scalability of the platform technology and the possibility of additional technology transfers could positively contribute to enhancing corporate value.

The securities industry is noting the likelihood that selective buying will continue for biotech companies with clear growth potential, even amid expanding stock market volatility. However, some also advise that a cautious approach is necessary, as stock price volatility for biotech companies can increase significantly depending on major events such as clinical results, technology transfers, and regulatory approvals.

[This article was written with the assistance of AI. This article does not constitute investment advice, and the final decision and responsibility for investments lie solely with the investor.]